Fresh thoughts and perspectives on CARES study from viewpoint of an Asian physician: comment on the article by Choi et al.
Authors of this article are:
Wu X1,2, Li C1,3.
A summary of the article is shown below:
Following the report of CARES study published on NEJM and associated U.S. FDA’s safety alert concerning febuxostat for management of hyperuricemia in gout, Choi et al. provided a timely and insightful evaluation on CARES study, which well covered the significance of the trial, strength of the design, concerns on high discontinuation rate and so on. As a major urate-lowering therapy (ULT) drug which was used worldwide, release of CARES results and FDA alert had a profound impact on the society of gout and patient communities. This article is protected by copyright. All rights reserved.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as: n/a.
Categories: Science News